Analyst Price Targets — MDRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 19, 2024 2:09 am | George Hill | Deutsche Bank | $10.00 | $8.20 | StreetInsider | Deutsche Bank Downgrades Veradigm Inc (MDRX) to Hold |
| February 1, 2023 5:20 am | — | Piper Sandler | $18.50 | $17.91 | Benzinga | Piper Sandler Downgrades Veradigm to Neutral, Raises Price Target to $18.5 |
| November 18, 2022 7:56 am | — | J.P. Morgan | $20.00 | $18.72 | Benzinga | JP Morgan Maintains Underweight on Allscripts Healthcare, Raises Price Target to $20 |
| June 10, 2022 7:18 am | — | Piper Sandler | $17.00 | $16.92 | Benzinga | Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $17 |
| May 6, 2022 8:40 am | — | Piper Sandler | $19.00 | $19.02 | Benzinga | Piper Sandler Maintains Neutral on Allscripts Healthcare, Lowers Price Target to $19 |
Latest News for MDRX
CHICAGO--(BUSINESS WIRE)--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced the appointment of Christian Greyenbuhl as Chief Financial Officer of the Company, effective on the later of May 11, 2026 and the first business day after Veradigm files its Annual Report on Form 10-K for its 2023 and 2024 fiscal years, or as otherwise agreed. Mr.…
Veradigm Inc. (MDRX) Discusses Strategic Reset, Product Portfolio Decisions and Growth Initiatives Transcript
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, is providing estimated financial performance for the fiscal year 2025 and key areas of strategic focus for 2026. “On my first investor call in October, I committed to advancing three strategic objectives in my first 100 days: reset our business strategy, recover our market…
CHICAGO--(BUSINESS WIRE)--Veradigm (OTCMKTS:MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced a new patient‑reported outcomes (PRO) survey capability that brings the patient voice directly into real‑world evidence generation. The new solution gives life sciences organizations timely, privacy‑preserving insights directly from patients, adding essential…
CHICAGO--(BUSINESS WIRE)--Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, announced today that management plans to provide a business update after the close of regular stock market hours on February 17, 2026. Veradigm management plans to host an investor conference call and webcast to discuss the Company's update at 8:00 a.m. Eastern Time on February…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MDRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.